Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving
health through innovative tests that guide patient care, will share
data supporting its dermatologic portfolio of gene expression
profile (GEP) tests at the 2025 Winter Clinical Dermatology
Conference - Hawaii, taking place Feb. 14-19 in Waikoloa Village,
Hawaii.
“As long-standing supporters of the Winter Clinical Dermatology
Conferences, we aim to facilitate meaningful conversations on
advancing patient care,” said Rebecca Critchley-Thorne, Ph.D., vice
president of research and development at Castle Biosciences. “The
data we are sharing reinforces our commitment to improving the care
of patients with skin cancers through innovative tests that can
guide more informed disease management decisions.”
Details regarding Castle’s posters are included below. Posters
will be available for viewing in the Queen's Ballroom 5-6 for the
duration of the conference.
DecisionDx®-Melanoma Poster title: The i31-SLNB
identifies patients with cutaneous melanoma who have less than 5%
risk of SLN positivity while the CP-GEP does not Lead Author:
J. Michael Guenther, M.D., St. Elizabeth Physicians General &
Vascular Surgery, Edgewood, Kentucky
DecisionDx®-SCC Poster title: Use of the 40-gene
expression profile (40-GEP) test to identify immunosuppressed
patients with Brigham and Women’s Hospital (BWH) T1-T2a cutaneous
squamous cell carcinoma (cSCC) at higher risk of metastasis:
Implications for adjuvant radiation Lead Author: Karina Brito,
BS, Department of Radiation Oncology, Cleveland Clinic, Cleveland,
Ohio
MyPath® Melanoma Poster title: Enabling access to
prognostic gene expression profile (GEP) testing for invasive
melanoma by leveraging RNA-based testing in the diagnostic
workflow Lead Author: Brooke H Russell, Ph.D., Castle
Biosciences, Inc., Friendswood, Texas
Additional information regarding these posters and Castle’s
participation at Winter Clinical can be found at the company’s
booth, located in the exhibit hall on the Grand Promenade.
About DecisionDx-Melanoma
DecisionDx-Melanoma is a gene expression profile risk
stratification test. It is designed to inform two clinical
questions in the management of cutaneous melanoma: a patient’s
individual risk of sentinel lymph node positivity and a patient's
personal risk of melanoma recurrence and/or metastasis. By
integrating tumor biology with clinical and pathologic factors
using a validated proprietary algorithm, DecisionDx-Melanoma is
designed to provide a comprehensive and clinically actionable
result to guide risk-aligned patient care. DecisionDx-Melanoma has
been shown to be associated with improved patient survival and has
been studied in more than 10,000 patient samples.
DecisionDx-Melanoma’s clinical value is supported by more than 50
peer-reviewed and published studies, providing confidence in
disease management plans that incorporate the test’s results.
Through Sept. 30, 2024, DecisionDx-Melanoma has been ordered
approximately 183,000 times for patients diagnosed with cutaneous
melanoma. Learn more at www.CastleBiosciences.com.
About DecisionDx-SCC
DecisionDx-SCC is a 40-gene expression profile test that uses an
individual patient’s tumor biology to stratify risk of metastasis
in patients with cutaneous squamous cell carcinoma who have one or
more NCCN high-risk factors. The test result, in which patients are
stratified into a Class 1 (low), Class 2A (higher) or Class 2B
(highest) risk category, predicts individual metastatic risk to
inform risk-appropriate management and guide decision-making
regarding the use of adjuvant radiation therapy. Peer-reviewed
publications have demonstrated that DecisionDx-SCC is an
independent predictor of metastatic risk and that the test can
significantly improve risk-stratification when used with
traditional staging systems and clinicopathologic risk factors to
guide risk-aligned management and treatment decisions. Learn more
at www.CastleBiosciences.com.
About MyPath Melanoma
MyPath Melanoma is Castle’s gene expression profile test
designed to provide an accurate, objective result to aid
dermatopathologists and dermatologists in characterizing
difficult-to-diagnose melanocytic lesions. Of the approximately two
million suspicious pigmented lesions biopsied annually in the U.S.,
Castle estimates that approximately 300,000 of those cannot be
confidently classified as either benign or malignant through
traditional histopathology methods. For these cases, the treatment
plan can also be uncertain. Obtaining accurate, objective ancillary
testing can mean the difference between a path of overtreatment or
the risk of undertreatment. Interpreted in the context of other
clinical, laboratory and histopathologic information, MyPath
Melanoma is designed to reduce uncertainty and provide confidence
for dermatopathologists and help dermatologists deliver more
informed patient management plans. Learn more at
www.CastleBiosciences.com.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics
company improving health through innovative tests that guide
patient care. The Company aims to transform disease management by
keeping people first: patients, clinicians, employees and
investors.
Castle’s current portfolio consists of tests for skin cancers,
Barrett’s esophagus, mental health conditions and uveal melanoma.
Additionally, the Company has active research and development
programs for tests in these and other diseases with high clinical
need, including its test in development to help guide systemic
therapy selection for patients with moderate-to-severe atopic
dermatitis seeking biologic treatment. To learn more, please visit
www.CastleBiosciences.com and connect with us on LinkedIn,
Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR,
DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, TissueCypher,
IDgenetix, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are
trademarks of Castle Biosciences, Inc.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, which are subject to the “safe harbor” created by those
sections. These forward-looking statements include, but are not
limited to, statements concerning: Castle’s ability to facilitate
meaningful conversations on advancing patient care; and the ability
of Castle’s test portfolio to improve the care of patients with
skin cancers and AD. The words “believe,” “can,” “could,”
“potential” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. We may not actually
achieve the plans, intentions or expectations disclosed in our
forward-looking statements, and you should not place undue reliance
on our forward-looking statements. Actual results or events could
differ materially from the plans, intentions and expectations
disclosed in the forward-looking statements that we make. These
forward-looking statements involve risks and uncertainties that
could cause our actual results to differ materially from those in
the forward-looking statements, including, without limitation:
subsequent study or trial results and findings may contradict
earlier study or trial results and findings or may not support the
results obtained in these studies, including with respect to the
discussion of our tests in this press release; actual application
of our tests may not provide the aforementioned benefits to
patients; and the risks set forth under the heading “Risk Factors”
in our Annual Report on Form 10-K for the year ended December 31,
2023, our Quarterly Report on Form 10-Q for the quarter ended
September 30, 2024 and in our other filings with the SEC. The
forward-looking statements are applicable only as of the date on
which they are made, and we do not assume any obligation to update
any forward-looking statements, except as may be required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250212186377/en/
Investor Contact: Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact: Allison Marshall
amarshall@castlebiosciences.com
Castle Biosciences (NASDAQ:CSTL)
Gráfico Histórico do Ativo
De Fev 2025 até Mar 2025
Castle Biosciences (NASDAQ:CSTL)
Gráfico Histórico do Ativo
De Mar 2024 até Mar 2025
